Moss Genomics, Inc.

Moss Genomics, Inc.

0.02
CAD
+0.01
(+50.00%)
-0.01EPS
4.76MMarket Cap

Total Valuation

CAD

As of March 31, 2026, Moss Genomics, Inc. carries a market capitalization of 4.76M, placing it among publicly traded companies globally. Its enterprise value stands at 4.74M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap4.76M
Enterprise Value4.74M

Share Statistics

As of March 31, 2026, Moss Genomics, Inc. has 63.41M shares outstanding.

Shares Outstanding63.41M

Valuation Ratios

These figures are as of March 31, 2026.

PB Ratio4.20
P/TBV Ratio4.20
P/FCF Ratio-35.43
P/OCF Ratio-35.43

Financial Position

As of March 31, 2026, Moss Genomics, Inc. maintains a current ratio of 7.48, meaning it holds 7.5x the short-term assets needed to cover near-term liabilities.

Current Ratio7.48
Quick Ratio0.26
Interest Coverage-285.45

Financial Efficiency

Over the twelve months ended March 31, 2026, Moss Genomics, Inc. posted a negative return on equity (ROE) of -113.27, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -90.70, reflecting losses generated across the asset base.

Return on Equity (ROE)-113.27
Return on Assets (ROA)-90.70

Stock Price Statistics

CAD

As of the close on October 19, 2026, Moss Genomics, Inc.'s stock has declined approximately 70.00% over the past 52 weeks. The 50-day moving average sits at 0.04, while the 200-day moving average is 0.12.

52-Week Price Change-70.00%
50-Day Moving Average0.04
200-Day Moving Average0.12

Income Statement

CAD

Over the twelve months ended March 31, 2026, Moss Genomics, Inc. generated - - in revenue and converted that into -823,378.00 in net income, yielding earnings per share of -0.01. EBITDA reached -221,511.00, while operating income came in at -241,511.00.

Operating Income-241,511.00
Pretax Income-823,338.00
Net Income-823,378.00
EBITDA-221,511.00
EBIT-241,511.00
Earnings Per Share (EPS)-0.01

Balance Sheet

CAD

These figures are as of March 31, 2026. Total book value stands at 1.13M, with working capital of 1.13M providing operational flexibility.

Cash & Cash Equivalents11,912.00
Net Debt-11,912.00
Equity (Book Value)1.13M
Book Value Per Share0.02
Working Capital1.13M

Cash Flow

CAD

Moss Genomics, Inc. produced -126,095.00 in operating cash flow over the twelve months ended March 31, 2026.

Operating Cash Flow-126,095.00
Free Cash Flow-126,095.00

Dividends & Yields

These figures cover the twelve months ended March 31, 2026. Free cash flow yield is negative at -2.82: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -2.00, meaning Moss Genomics, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Shareholder Yield-2.00
FCF Yield-2.82

Scores

As of March 31, 2026, Moss Genomics, Inc. has an Altman Z-Score of 13.44, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score13.44